Vaccine · 2023
Recombinant measles virus encoding the spike protein of SARS-CoV-2 efficiently induces Th1 responses and neutralizing antibodies that block SARS-CoV-2 variants.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kwak Hye Won, Park Hyo-Jung, Jung Seo-Yeon, Oh Eun Young, Park Sang-In, Kim Yeonhwa, Park Hyeong-Jun, Park Sohyun, Kim You-Jin, Ko Hae Li, Lee Jung-Ah, Won Hyeran, Hwang Yun-Ho, Kim Seo Yeon, Kim Se Eun, Bae Seoung Eun, Yoon Minhyuk, Kim Jae-Ouk, Song Manki, Lee Su Jeen, Seo Ki-Weon, Lee Kunse, Kim Dokeun, Kim Hun, Lee Sang-Myeong, Hong So-Hee, Nam Jae-Hwan
Аннотация
Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.